Abstract 785P
Background
GTN involves malignant entities, such as choriocarcinoma (GCC), epithelioid trophoblastic tumor (ETT), and placental site trophoblastic tumor (PSTT), all of which can metastasize and be fatal if not treated in a timely and effective manner. We aimed to develop machine-learning (ML)-based prognostic models for patients with GTN to improve treatment decisions and personalized medicine.
Methods
The SEER database provided the data used for this study’s analysis (2000–2019). Patients were excluded if they did not meet certain criteria, such as a histology-confirmed diagnosis, previous history of cancer or other concurrent malignancies, non-placental origins, or unknown data. Cox regression and ML algorithms were used to construct prognostic models for predicting the 5-year survival. Patient records were randomly divided into a training set (70%) and a validation set (30%). A validation method incorporating the area under the curve (AUC) of the receiver operating characteristic curve was used to validate the accuracy and reliability of ML models.
Results
This study included 725 patients, of whom 139 had ETT, 107 had PSTT, and 479 had GCC. The median age was 37 years, and the most common stage was distant metastasis (n=330). The average tumor size was 6.13 cm, and 75.9% of patients underwent chemotherapy, 57.9% underwent surgery, and 4.3% underwent radiotherapy. Multivariate Cox regression revealed that older age, marital status, metastasis, and radiotherapy were poor prognostic factors, whereas surgery was a good prognostic factor. ML models revealed that the most important factors that influenced the model prediction performance were tumor size, years of diagnosis, and race. The online calculator, which is based on ML models, allows for real-time personalized survival predictions, and can be accessed through the following link: https://sakhrshwayyat.shinyapps.io/Gestational_Trophoblastic_Neoplasia/.
Conclusions
Our study revealed the critical components of clinical decision-making. The designed models and online prediction resources can significantly facilitate personalized treatment planning and enhance the clinical outcomes of patients with GTN.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
870P - POPPY: A phase II trial to assess the efficacy and safety profile of pembrolizumab in patients of performance status 2 with recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC)
Presenter: Martin Forster
Session: Poster session 02
871P - Randomized phase II trial of nivolumab plus paclitaxel in subjects with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) unable for cisplatin (CP)-based chemotherapy (CT): NIVOTAX TTCC study
Presenter: Lara Iglesias Docampo
Session: Poster session 02
873P - Nivolumab (NIVO) in the first-line (1L) or second-line (2L) and later (2L+) settings in patients (pts) with recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M SCCHN): Updated results from the German non-interventional study (NIS), HANNA
Presenter: Andreas Dietz
Session: Poster session 02
874P - Preliminary outcomes from a phase Ib/II study of WX390 combined with toripalimab in patients with recurrent or metastatic head and neck squamous cell carcinoma
Presenter: Ye Guo
Session: Poster session 02
875P - A phase II clinical trial of camrelizumab combined with cetuximab and chemotherapy in recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Dongmei Ji
Session: Poster session 02
876P - Evaluation of the safety and efficacy of ivonescimab in combination with ligufalimab as first-line (1L) treatment for PD-L1 positive recurrent/metastasis head and neck squamous cell carcinoma (R/M HNSCC)
Presenter: Xiaozhong Chen
Session: Poster session 02
878P - Final results of a phase II study of peltopepimut-S and cemiplimab in patients with relapsed/metastatic HPV16+ oropharyngeal cancer that progressed with prior anti-PD-1 therapy
Presenter: Anthony Kong
Session: Poster session 02
879P - VERSATILE-002: Survival with first-line treatment with PDS0101 therapeutic vaccine and pembrolizumab in HPV16-positive recurrent/metastatic head and neck squamous cell carcinoma (HNSCC)
Presenter: Jared Weiss
Session: Poster session 02